Influvac Tetra

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredients in Influvac Tetra, are a quadrivalent influenza vaccine presented as a sterile injectable suspension for intramuscular or subcutaneous use. It stimulates immunity to protect against seasonal influenza infection in eligible individuals.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Influvac Tetra is indicated for immunization against influenza viruses within the seasonal flu disease family. - Seasonal influenza: provides protection against the four influenza virus strains included in the vaccine, reducing the risk of infection. - High‑risk populations: helps lower the incidence of flu‑related complications in elderly, pregnant persons, and individuals with chronic medical conditions. - Outbreak control: contributes to community immunity during influenza epidemics, supporting public health vaccination programs.

Like other inactivated influenza vaccines, Influvac Tetra may be associated with local and systemic reactions. Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema around the injection area. - Low‑grade fever: transient temperature rise, usually ≤38.5 °C. - Headache: mild headache occurring within 24 hours post‑vaccination. - Myalgia: muscle aches that resolve spontaneously. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially linked to vaccination. - Seizures: infrequent occurrence, particularly in children with fever. - Thrombocytopenia: low platelet count observed rarely after vaccination.

Prior to administering Influvac Tetra, healthcare professionals should observe the following precautions. - Allergy assessment: avoid use in individuals with a known severe allergy to any vaccine component. - Fever evaluation: defer vaccination if the recipient has a moderate or high fever at the time of injection. - Recent vaccine history: postpone administration if another vaccine was given within 14 days to reduce reactogenicity. - Immunocompromised status: consider reduced immunogenicity in patients with severe immunosuppression. - Pregnancy and lactation: assess risk‑benefit; data are limited, so use only if clearly indicated. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra may interact with certain medical products; awareness of these interactions helps ensure safe vaccination. Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference with immune response. - Immunoglobulin therapy: concurrent administration may diminish vaccine efficacy. - Antiviral medications: avoid within 48 hours before or after vaccination as they may affect antibody development. Moderate Interactions (Monitor Closely): - Other injectable vaccines: simultaneous injection may increase local reactogenicity; monitor injection sites. - Antipyretics: prophylactic use may blunt antibody response; advise use only after vaccination if needed. - Corticosteroids: high‑dose systemic steroids may reduce immunogenicity; assess timing relative to vaccination.